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SGLT2 inhibitor therapy improves blood glucose but does not 
prevent diabetic bone disease in diabetic DBA/2J male mice
Kathryn M. Thrailkill, MDa, R. Clay Bunn, PhDa, Jeffry S. Nyman, PhDb, Mallikarjuna R. 
Rettiganti, PhDc, Gael E. Cockrellc, Elizabeth C. Wahlc, Sasidhar Uppugantib, Charles K. 
Lumpkin Jr., PhDc, and John L. Fowlkes, MDa
aUniversity of Kentucky Barnstable Brown Diabetes and Obesity Center and the Department of 
Pediatrics, University of Kentucky College of Medicine, Lexington, KY 40536
bVA Tennessee Valley Health Care System, Department of Orthopaedic Surgery & Rehabilitation 
and Center for Bone Biology, Vanderbilt University Medical Center, Nashville, TN 37232
cDepartment of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's 
Hospital Research Institute, Little Rock, AR, 72202, USA
Abstract
Persons with type 1 and type 2 diabetes have increased fracture risk, attributed to deficits in the 
microarchitecture and strength of diabetic bone, thought to be mediated, in part, by the 
consequences of chronic hyperglycemia. Therefore, to examine the effects of a glucose-lowering 
SGLT2 inhibitor on blood glucose (BG) and bone homeostasis in a model of diabetic bone 
disease, male DBA/2J mice with or without streptozotocin (STZ)-induced hyperglycemia were fed 
chow containing the SGLT2 inhibitor, canagliflozin (CANA), or chow without drug, for 10 weeks 
of therapy. Thereafter, serum bone biomarkers were measured, fracture resistance of cortical bone 
was assessed by μCT analysis and a three-point bending test of the femur, and vertebral bone 
strength was determined by compression testing. In the femur metaphysis and L6 vertebra, long-
term diabetes (DM) induced deficits in trabecular bone microarchitecture. In the femur diaphysis, 
a decrease in cortical bone area, cortical thickness and minimal moment of inertia occurred in DM 
(p<0.0001, for all) while cortical porosity was increased (p<0.0001). These DM changes were 
associated with reduced fracture resistance (decreased material strength and toughness; decreased 
structural strength and rigidity; p<0.001 for all). Significant increases in PTH (p<0.0001), 
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RatLAPs (p=0.0002), and urine calcium concentration (p<0.0001) were also seen in DM. 
Canagliflozin treatment improved BG in DM mice by ~35%, but did not improve 
microarchitectural parameters. Instead, in canagliflozin-treated diabetic mice, a further increase in 
RatLAPs was evident, possibly suggesting a drug-related intensification of bone resorption. 
Additionally, detrimental metaphyseal changes were noted in canagliflozin-treated control mice. 
Hence, diabetic bone disease was not favorably affected by canagliflozin treatment, perhaps due to 
insufficient glycemic improvement. Instead, in control mice, long-term exposure to SGLT2 
inhibition was associated with adverse effects on the trabecular compartment of bone.
Keywords
Diabetic bone disease; type 1 diabetes; trabecular bone; cortical bone; microarchitecture; 
canagliflozin
1.1 Introduction
Osteopenia, osteoporosis and risk for fracture are all increased in persons with type 1 
diabetes (T1D), with a propensity for fracture that is greater than would be predicted by 
bone mineral density (BMD) alone (1, 2). Hence, the impact of chronic hyperglycemia on 
bone quality and bone microarchitecture is relevant to diabetic bone disease. Renal glucose 
resorption is regulated by the sodium glucose co-transporter 2 (SGLT2), a high affinity 
transporter expressed in the proximal tubule. SGLT2 inhibitors, by inhibiting reabsorption of 
filtered glucose in the renal proximal tubule, lower blood glucose levels in persons with 
diabetes, independent of insulin action or secretion and without inducing hypoglycemia (3). 
Consequently, they have been shown to improve HbA1c in persons with type 2 diabetes 
(T2D) (3). Currently, T1D is not a Food and Drug Administration (FDA)-approved 
indication for SGLT2 inhibitor therapy, although registered clinical trials in T1D are 
underway (ClinicalTrials.gov Identifier:NCT02139943), and are supported by proof-of-
concept trials which demonstrate glycemic improvement from SGLT2 adjunctive-to-insulin 
treatment in T1D (4), as well as from dual SGLT1/SGLT2 inhibitor adjunctive-to-insulin 
treatment in T1D (5). Early clinical investigation in T2D, however, has demonstrated a 
possible ~30% increase in bone fractures in patients receiving the SGLT2 inhibitor, 
canagliflozin (6). Therefore, using a mouse model of diabetic bone disease which is 
characterized by insulin deficiency (i.e., streptozotocin-induced diabetes), we examined the 
effects of 10 weeks of treatment with the SGLT2 inhibitor, canagliflozin (CANA) on bone 
microarchitecture and material strength of the appendicular and axial skeleton, as a 
preclinical investigation of the skeletal impact of SGLT2 inhibitor therapy in T1D.
1.2 Materials and Methods
1.2.1 Animal model
The DBA/2J strain of mice (The Jackson Laboratories, Bar Harbor, Maine) exhibits a 
propensity for the development of diabetic complications (7), and as we have previously 
shown, develops a diabetic bone phenotype within 10 weeks of hyperglycemia (8). Male 
DBA/2J mice, 10–11 weeks of age, were treated either with streptozotocin (STZ) to induce 
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diabetes (40 mg/kg/day × 5 days) or with vehicle (100 mM citrate, pH 4.5). At ~12–13 
weeks of age, diabetic mice, as confirmed by glucosuria, were then randomly assigned to 
treatment groups as follows; DBA/2J mice with streptozotocin (STZ)-induced diabetes were 
either fed Teklad 8640 chow containing the SGLT2 inhibitor, canagliflozin (STZ+CANA, 
50 ppm, n=19) or chow without canagliflozin (STZ+VEHICLE, n=18). Non-diabetic 
(control) mice were fed chow containing a slightly higher canagliflozin concentration 
(CONT+CANA, 62.5 ppm; to approximately offset the polyphagia in diabetic mice; n=20), 
or chow without canagliflozin (CONT+VEHICLE, n=20). Mice were provided ad libitum 
access to water and to their assigned food for the next 10 weeks. Based on differing rates of 
food consumption between diabetic and non-diabetic animals, canagliflozin intake during 
the 10 week treatment period was 17.7–20.6 mg/kg/day (mean ± SD; 18.7 ± 1.0) in the STZ 
(diabetes) group and 14.2–19.6 mg/kg/day (16.6 ± 2.0) in the non-diabetes group. Blood 
glucose was measured at 3 and 10 weeks of treatment, via glucometer (OneTouch® Ultra®2 
Blood Glucose Monitoring System, Lifescan, Inc., Milpitas, CA; average intra-assay 
coefficient of variation, 1.7% across a range of 40–300 mg/dL target glucose 
concentrations). All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Arkansas for Medical Sciences.
1.2.2 Skeletal Assessment
After euthanasia, the left femur was harvested and femur length was measured using 
calipers. Bones [femurs (all mice) and L6 vertebra (n=10 mice per group)] were frozen in 
phosphate buffered saline (PBS) and stored at −20°C until analysis. With each femur 
immersed in PBS at room temperature, the long axis of the bone was scanned with a micro-
computed tomography (μCT) scanner (Scanco Medical µCT40, Brϋttisellen, Switzerland): 
voxel size of 12 μm, energy settings of 70 kVp/0.114 mA, integration time of 300 ms with 
1000 projections per full rotation, and calibrated to a hydroxyapatite (HA) phantom, as we 
have previously described (7). Likewise, the cranial-caudal axis of each L6 vertebral body 
(VB) was aligned with the long axis of the specimen tube and scanned while immersed in 
PBS using another μCT scanner (Scanco Medical μCT50, Brϋttisellen, Switzerland): voxel 
size of 10 μm, energy settings of 55 kVp/0.20 mA, integration time of 1200 ms with 1000 
projections per full rotation, and calibration to a HA phantom. For the femur, the regions of 
interest (ROI) included the trabecular bone of the metaphysis and the cortical bone of the 
diaphysis (1.2 mm in length for both compartments). For the VB, the ROI included the 
trabecular bone between the end-plates and within the cortical shell. Each ROI had a unique 
threshold (465.7 mgHA/cm3 and 912.6 mgHA/cm3 for trabecular and cortical bone of the 
femur, respectively and 304.3 mgHA/cm3 for trabecular bone of the VB) and Gaussian noise 
filter (sigma of 0.2 with support of 1 for both trabecular and cortical bone) used for all scans. 
Standard evaluation scripts from the manufacturer were used to determine the architectural 
and structural properties of trabecular and cortical bone, respectively.
1.2.3 Biomechanical Testing
To determine mechanical properties of cortical bone, each hydrated femur or each hydrated 
VB was loaded to failure at 3 mm/min using a three-point bending fixture (bending about 
the medial-lateral plane) or using compression platens with a moment relief, respectively. 
The span between the lower supports was 8 mm. From the resulting forces recorded by a 
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100 N load cell (Honeywell; Morristown, NJ) and displacements recorded by the LVDT 
(Dynamight 8841, Instron; Canton, OH) structural properties included the initial stiffness 
and the peak force endured by the femur. Material properties of modulus and strength of the 
cortex were also estimated using standard beam theory. The μCT scans provided the 
moment of inertia (Imin) and the distance between the neutral axis of bending and the 
outermost point in the anterior-posterior direction (Cmin). For the compression tests, we 
recorded the peak force as the measurement of whole-bone strength of the VB (Force) and 
divided the peak force by the mean estimated cross-sectional area as the measurement of the 
apparent strength of the VB (Stress).
1.2.4 Bone Biomarker Analyses
For all mice in all groups, procollagen type 1 N-terminal propeptide (P1NP), a marker of 
bone formation, was measured in serum at sacrifice, using the Rat/Mouse P1NP Enzyme 
immunoassay (Immunodiagnostics Systems, Inc., Fountain Hills, AZ; #AC-33F1); C-
terminal telopeptides of type I collagen (RatLAPs), a marker of bone resorption, was 
measured in serum using the RatLAPs ELISA (Immunodiagnostics Systems, Inc., Fountain 
Hills, AZ; #AC-06F1). Due to limitations in serum availability, for a smaller subset of mice 
(STZ+CANA, n=10; STZ+VEH, n=13; CONT+VEH, n=17), osteoclast-derived, tartrate-
resistant acid phosphatase (TRACP 5b) activity, a marker of osteoclast number, was 
measured. TRACP 5b activity was measured using the MouseTRAP™ ELISA 
(Immunodiagnostics Systems, Inc., Fountain Hills, AZ; #SB-TR103).
To assess the consequences of SGLT2-induced osmotic diuresis on urinary mineral loss, we 
also examined select components of calcium and phosphate homeostasis. Using urine 
collected from each animal within one week of sacrifice, urine calcium was measured using 
a calcium colorimetric assay (Sigma-Aldrich Corporation, St. Louis, MO; #MAK022) and 
urine creatinine was measured using an alkaline picrate chemical assay (Exocell, Inc., 
Philadelphia, PA; The Creatinine Companion, #1012). Calcium concentration was then 
normalized to urine creatinine concentration, and reported as a calcium/creatinine ratio 
(CCR). Mouse intact parathyroid hormone (PTH 1–84), indicative of serum calcium and 
phosphate regulation, was measured in plasma at sacrifice using the mouse two-site ELISA 
(Alpco Diagnostics, Salem, NH; #31-PTHMS-E01). FGF23, a bone-derived marker of 
chronic kidney disease that functions to inhibit renal reabsorption of phosphate, independent 
of PTH (8), was measured using the MILLIPLEX MAP Mouse Bone Magnetic Bead kit (# 
MBNMAG-41K) for FGF23.
1.2.5 Quantitative RT-PCR
To quantify disease or drug-induced changes in renal expression of genes involved in 
calcium and phosphate regulation, quantitative RT-PCR was performed essentially as 
described by Fowlkes, et al, (9) using the following primers: 25-hydroxyvitamin D-1 alpha 
hydroxylase (CYP27B1), forward: 5' acggcggatggtgaagaatg 3', reverse: 5' 
ttgtccagagttccagcatagc 3'; and the solute carrier family 34 (type II sodium/phosphate 
cotransporter, member 1, SLC34A1), forward: 5' caacatctcgggcatcctactg 3', reverse: 5' 
ggcaagagcaggaagcacac 3'. Target mRNA expression was normalized to actin expression to 
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control for cDNA loading variation (actin primers: forward: 5' tctggcaccacaccttctaca 3', 
reverse: 5' cagccaggtccagacgcagga 3').
1.2.6 Statistical Analyses
All data were checked for inconsistencies and outliers. Highly influential observations were 
removed prior to analysis. A one-way analysis of variance (ANOVA) was performed to test 
whether the means of several bone parameters were equal between the four groups: STZ
+CANA, STZ+VEH, CONT+CANA, CONT+VEH. Linear contrasts for the group variable 
were used to test the following four pairwise comparisons: STZ+CANA vs. STZ+VEH, 
CONT+CANA vs. CONT+VEH, STZ+CANA vs. CONT+CANA, and STZ+VEH vs. 
CONT+VEH. For each parameter, a step-down Bonferroni method was used to keep the 
overall family-wise error rate under 0.05 to adjust for multiple comparisons.
Pearson's correlation was used to test whether there was any association between PTH, 
P1NP, RatLAPs, FGF23, and CCR with other skeletal (diaphysis and metaphysis) 
parameters. Variables violating the normality assumption were log-transformed prior to 
analysis. All tests were two-sided assuming a significance level of 5%. All statistical 
analyses were generated using SAS/STAT software, Version 9.4 of the SAS System for 
Windows 7, Copyright © 2002–2012 SAS Institute Inc.
1.3 Results
Changes in body weight and blood glucose across the ten-week treatment period are shown 
in Table 1. Selected bone parameters, as determined by μCT and biomechanical testing, are 
also shown in Table 1. Representative μCT images are shown in Figure 1. Serum and urine 
bone biomarker concentrations are demonstrated in Figure 2. Relevant gene expression is 
compared in Figure 3.
1.3.1 Metabolic effects
Throughout 10 weeks of canagliflozin treatment, body weights and blood glucose levels 
were not significantly different between the two control groups (Table 1: CONT+CANA vs. 
CONT+VEH). In contrast, both groups of diabetic mice (STZ+CANA, STZ+VEH) 
exhibited hyperglycemia and weight loss, relative to their non-diabetic counterparts.
1.3.2 Effect of diabetes on bone microarchitecture, material and structural qualities of the 
appendicular skeleton
When examining bone quality, consistent with our previous findings (10), long-term 
diabetes was associated with deficits in trabecular bone microarchitecture in the femur 
(Table 1: Diaphysis, Metaphysis; P4), including decreased trabecular bone volume fraction 
(BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th) and tissue mineral density 
(Tb.TMD), along with increased trabecular spacing (Tb.Sp; p<0.0001 for all parameters) 
and changes in trabecular shape (SMI; p=0.002). Deficits in cortical bone content were also 
evident, characterized by decreased cortical area (Ct.AR, p<0.0001; Tt.AR, p=0.004) and 
cortical thickness (Ct.Th; p<0.0001), coupled with an increase in cortical porosity 
(p<0.0001). These DM changes were associated with a reduced resistance to fracture. 
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Specifically, with respect to material properties, bending strength and toughness were 
decreased in diabetic mice. As for whole-bone, structural properties, specifically structural 
strength (peak moment) and stiffness (rigidity) were lower for diabetic than for non-diabetic 
mice (p<0.0001 for all). These deficits in bone structure are depicted in representative μCT 
images (Figure 1B, compared with 1D).
1.3.3 Effects of diabetes on bone microarchitecture and strength of the axial skeleton
We have not previously reported on vertebral bone strength and quality in this model. 
Analysis of the L6 vertebra, as shown in Table 1, demonstrated that long-term diabetes was 
also associated with deficits in trabecular microarchitecture (significant decreases in 
Tb.BV/TV and Tb.TMD). Moreover, diabetic vertebrae were significantly less resistant to 
fracture by compression testing (Force).
1.3.4 Effects of diabetes on bone biomarkers
Measurements of P1NP, a marker of bone formation, were no different between diabetic and 
control groups (Figure 2B). However, secondary hyperparathyroidism (Figure 2A; 
p<0.0001), along with significant increases in urine calcium concentration (Table 1; CCR; 
p<0.0001), and serum RatLAPs (a marker of bone resorption) (Figure 2C; p=0.0002) were 
all evident in DM.
TRACP 5b (a marker of osteoclast number) was also increased in DM (STZ+VEH, 12.0 ± 
3.0 U/L vs. CONT+VEH, 9.8 ± 1.6 U/L, p=0.06; STZ+CANA, 13.5 ± 4.3 U/L vs. CONT
+CANA, 9.8 ± 1.4 U/L, p=0.002) and the overall effect of disease on TRACP 5b was 
significant (p<0.0001); however, perhaps due to the reduced sample size for this particular 
assay, the increase was not significant when comparing STZ+VEH with CONT+VEH 
(p=0.06).
Regarding biomarkers that were significantly increased in DM, RatLAPs was negatively 
associated with Ct.Th (r=−0.56; p=0.02), Ct.TMD (r=−0.59; p=0.01), Tb.Th (r=−0.49; 
p=0.04), Tb.TMD (r=−0.49; p=0.05) and peak moment (r=−0.53; p=0.03) in untreated 
diabetic mice (STZ+VEH). CCR was negatively associated with Ct.TMD (r=−0.52; p=0.03) 
and Tb.N (r=−0.56; p=0.02), while being positively associated with Tb.Sp (r=0.58; p=0.01). 
Serum PTH, however, was not specifically related to cortical or trabecular bone parameters, 
either in untreated diabetic mice (STZ+VEH), or in both diabetic groups when combined 
(STZ+VEH, STZ+CANA), suggesting that differences in PTH did not explain the 
differences in bone phenotype.
1.3.5 Effects of Canagliflozin treatment in diabetic and non-diabetic mice
Consistent with treatment expectations, canagliflozin intake by diabetic mice decreased 
mean blood glucose levels from 520.94 ± 84.69 mg/dL to 358.84 ± 72.3 mg/dL after 3 
weeks and from 525.18 ± 53.64 mg/dL to 338.89 ± 131.45 mg/dL after 10 weeks of 
treatment (mean ± SD; p<0.0001 for both comparisons). This glucose improvement was not, 
however, associated with recovery of any of the trabecular or cortical microarchitecture 
parameters [Table 1 (P1); Figure 1A vs. 1B]. Moreover, canagliflozin treatment did not 
prevent the diabetes-related decrease in the fracture resistance of either the femur or L6 
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vertebra [Table 1 (P1, P3)]. Specifically, bending strength, toughness, peak moment, 
rigidity, and force were all lower for canagliflozin-treated diabetic mice, compared with 
canagliflozin-treated non-diabetic mice. However, when comparing the STZ+CANA and 
STZ+VEH groups, a further increase in serum RatLAPs was evident in canagliflozin-treated 
diabetic mice (Figure 2C).
Canagliflozin treatment of control mice did not significantly alter blood glucose levels or 
body weight (Table 1). However, canagliflozin treatment of control mice did reduce femoral 
trabecular BV/TV, Tb.N and Tb.TMD, while increasing Tb.SP (Table 1, P2), suggesting 
detrimental drug-induced metaphyseal changes in control animals. Urine calcium excretion 
(CCR; p=0.003) in canagliflozin-treated control mice was also significantly increased, as 
were levels of serum FGF23 (a regulator of urine phosphate excretion; Figure 2D, p=0.046), 
possibly suggesting a subclinical but compensatory hyperparathyroidism in this group, in 
response to increased urine calcium losses.
1.3.6 CYP27B1 and SLC34A1 gene expression
Differences in renal gene expression of CYP27B1 and SLC34A1 were evident between 
diabetic and non-diabetic mice. Specifically, expression of CYP27B1 mRNA was increased 
by ~11-fold (p<0.0001) and expression of SLC34A1 was decreased by ~30% (p=0.046) in 
diabetic mice (STZ+VEH) versus non-diabetic mice (CON+VEH) (Figure 3). Canagliflozin 
treatment reduced by 50% the expression of CYP27B1 mRNA in diabetic mice (STZ
+CANA vs. STZ+VEH, p=0.012), but did not change SLC34A1 expression. Canagliflozin 
treatment of control mice did not significantly impact the expression of either gene.
1.4 Discussion
Increased bone fragility, contributing to increased fracture risk, is a significant comorbidity 
in persons with either type 1 diabetes (T1D) or type 2 diabetes (T2D); and is likely the 
consequence of many common variables, including chronic hyperglycemia, tissue-specific 
accumulation of advanced glycation end-products (AGEs) and secondary 
hyperparathyroidism. The SGLT2 inhibitor class of drugs enhances urinary glucose 
excretion by inhibiting the function of the renal sodium-glucose cotransporter-2 in the early 
proximal convoluted tubule. While beneficial for the treatment of hyperglycemia, the excess 
Na+ in the tubular lumen can alternatively be reabsorbed via the Na+-Phosphate transporter, 
thereby increasing serum phosphate concentration. The expected compensatory 
physiological response would include an increase in both parathyroid hormone (PTH) and 
fibroblast growth factor 23 (FGF23), leading to phosphaturia and a return to normo-
phosphatemia. Additionally, chronic glucosuria, both as a consequence of uncontrolled 
diabetes mellitus, or as augmented by SGLT2 inhibitor therapy, contributes to diabetic 
hypercalciuria via osmotic diuresis (11–13). Analogously, hypercalciuria is a reported 
comorbidity in some children with severe Familial Renal Glucosuria, a disorder attributed to 
mutations in the gene for SGLT2 (slc5a2) (14), suggesting that SGLT2 drug exposure might 
augment urinary calcium loss in diabetes, despite improving glycemic control. Taken 
together, a “perfect storm” of factors detrimental to bone mineral homeostasis could exist, 
particularly in patients receiving long-term treatment with SGLT2 inhibitors.
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The present study was designed to examine the effects of long-term treatment with the 
SGLT2 inhibitor, canagliflozin, on bone biomarkers, bone microarchitecture and material 
strength of bone in a mouse model of diabetic bone disease. Consistent with our previous 
reports (7, 10), deficits in both cortical and trabecular bone microarchitecture and bone 
strength in the femur were demonstrated in untreated diabetic animals. Additionally, bone 
quality and strength of diabetic vertebrae were compromised. Yet, while treatment of 
diabetic mice for 10 weeks with canagliflozin did improve blood glucose levels by ~35% 
throughout therapy, this degree of glucose improvement did not repair diabetes-related bone 
deficits, or improve fracture resistance of either the femur or L6 vertebra. Instead, drug 
treatment of diabetic mice was associated with increased bone resorption. Moreover, drug 
treatment of control mice was associated with increased calciuria, evidence of metaphyseal 
(trabecular) bone deterioration, and an increase in FGF23, possibly suggesting either a 
subclinical compensatory increase in PTH action in response to urine calcium losses, or a 
physiological consequence of canagliflozin-induced phosphate reabsorption.
In fact, the observed changes in renal gene expression (Figure 3) of CYP27B1 (~11-fold 
increase) and SLC34A1 (~30% decrease) in diabetic mice are as expected in a state of 
hyperparathyroidism, and are in keeping with the significant increase in serum PTH 
observed in diabetic mice (Figure 2A). These findings likely reflect acute physiological 
changes intended to offset the marked increase in urinary calcium excretion resulting from 
hyperglycemia-mediated osmotic diuresis in the diabetic groups. In contrast, while drug 
treatment of control mice did increase urinary calcium loss, relative to non-treated control 
animals, the magnitude of effect was not sufficient to significantly change mean serum PTH 
levels, or to influence gene expression of CYP27B1 or SLC34A1. Nevertheless, a modest, 
but significant increase in mean FGF23 concentration in the CONT+CANA group was 
detected, perhaps inferring a PTH-dependent osteocyte response to canagliflozin-induced 
increases in Na+-Phosphate reabsorption in the renal proximal tubule.
It could be argued that a canagliflozin-induced 35% drop in blood glucose, alone, was 
insufficient to rectify the skeletal consequences of hyperglycemia, and that nearer-
normalization of glycemic control, perhaps with higher drug doses, would be required. 
However, sub-maximal improvement in blood glucose levels is in accordance with the 
expected therapeutic efficacy seen in human clinical trials. For example, a meta-analysis of 
randomized trials demonstrated that dapagliflozin reduced fasting plasma glucose only 18.28 
mg/dL, when given as adjunct therapy to persons with T2D (15). Also, urinary glucose 
excretion during selective SGLT2-inhibitor treatment is only 30–40% of maximum in 
human studies (16, 17), possibly due to compensatory glucose reuptake by alternate glucose 
transporters. Correspondingly, studies comparing mice with an SGLT2 (slc5a2) single gene 
deletion to those with SGLT1 (slc5a1)/SGLT2 double gene knockout (DKO) suggest that 
renal SGLT1 in db/db mice has the capacity to reabsorb ~70% of filtered glucose when 
SGLT2 is non-functional (16, 18), again consistent with incomplete glucose improvement, 
as we report. Intrinsically, our study design was limited to the use of canagliflozin as 
monotherapy; further investigation would be needed to determine whether a multi-drug 
therapy, including SGLT2 inhibitors at comparable or higher doses, could provide a level of 
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glycemic improvement sufficient to prevent diabetic bone disease without undesirable 
consequences.
Alternatively, it could be suggested that canagliflozin, as an SGLT2 inhibitor, could impose 
a direct, detrimental pharmacological effect on bone cells themselves, either in the diabetic 
or non-diabetic mice, independent of the metabolic milieu. This hypothesis would, however, 
be dependent upon the expression of SGLT2 in bone cells. To our knowledge, while studies 
have demonstrated that high affinity glucose transporters (GLUTs) are expressed by 
osteoblasts (GLUT1 and GLUT3) and osteoclasts (Glut1) (22, 23), no information is 
currently available demonstrating expression of sodium-dependent glucose cotransporters 
(i.e. SGLT1 and SGLT2) in these cell types. Moreover, several studies show that expression 
of SGLT2 is limited to the brush border membrane of the proximal tubule cells of the kidney 
in rodents (19) and humans (20, 21). While the current study is limited in its ability to 
directly address this possibility, future studies could examine the expression of SGLT 
subtypes in bone cells, to determine if glucose transport in bone is affected by treatment 
with drugs such as canagliflozin.
The potential effects of SGLT2 inhibitors on healthy bone are of particular interest, given 
that the use of SGLT2 inhibitor therapy for therapeutic weight loss in humans has been 
proposed. In preclinical models of obesity, including Diet-induced obese (DIO) mice (22) 
and Zucker fatty (ZF) rats (22), SGLT2 inhibition for 3–4 weeks reduced body weight gain 
in treated rodents (22). Dual SGLT1/SGLT2 inhibition for 4 weeks has also been shown to 
significantly reduce body weight gain in lean animal models, including Sprague-Dawley rats 
and beagle dogs (23). Clinically, a recently published pilot study of the SGLT2 inhibitor, 
remogliflozin etabonate in obese non-diabetic individuals demonstrated a significant 
reduction in leptin/adiponectin ratio (a measure of insulin resistance) after 8 weeks of 
therapy (24), implying an improvement in the metabolic health of these individuals. In light 
of our findings which suggest possible drug-induced metaphyseal deficits in non-diabetic 
mice, it may become important to monitor the impact of longer-term SGLT2 inhibition on 
bone in all clinical conditions in which it is used.
1.5 Conclusions
In male diabetic DBA/2J mice, a sustained, ~35% therapeutic improvement in blood glucose 
control was achievable with long-term treatment with canagliflozin, given at doses of 17–20 
mg/kg/day. However, diabetic bone disease, as was evident in this model, was not favorably 
affected by this drug treatment, perhaps due to insufficient glycemic improvement. Instead, 
in control mice, long-term exposure to SGLT2 inhibition was associated with adverse effects 
on the trabecular compartment of bone, along with hypercalciuria. Our findings would 
suggest that as the clinical indications for SGLT2 inhibitor therapy expand, care should be 
taken to monitor skeletal health in persons receiving this class of drugs.
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Highlights
• Deficits in cortical and trabecular bone microarchitecture and in bone strength 
develop in untreated diabetic male DBA/2J mice.
• In these mice, treatment with the SGLT2 inhibitor, canagliflozin, for 10 weeks 
improved blood glucose levels by ~35%.
• Despite blood glucose improvement, canagliflozin treatment of diabetic mice 
did not improve diabetes-related bone deficits.
• Canagliflozin exposure may adversely modify skeletal tissues in both diabetic 
and non-diabetic male DBA/2J mice, possibly via increased bone resorption.
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Figure 1. Representative μCT images
A representative μCT image from each of the four groups is shown; STZ+CANA (A), STZ
+VEHICLE (B), CONTROL+CANA (C), and CONTROL+VEHICLE (D). Significant 
deficits in both cortical and trabecular bone were evident in mice with STZ-induced diabetes 
(A, B), compared with control mice (D). Specifically, as shown in these images, 
hyperglycemic mice exhibited decreased trabecular number (Tb.N) and increased trabecular 
spacing (Tb.Sp); decreased cortical thickness (Ct.Th) and increased cortical porosity (Ct.Po) 
can also be seen. Canagliflozin treatment did not improve diabetic bone disease, despite 
blood glucose reduction (A). In contrast, drug treatment of control mice (C) reduced 
trabecular bone volume fraction (BV/TV), Tb.N and trabecular tissue mineral density 
(Tb.TMD) while increasing Tb.Sp, compared to untreated control mice (D).
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Figure 2. Bone biomarker analyses
A comparison of serum bone biomarker concentrations (mean ± SD) across the four groups 
is shown; STZ+CANA, STZ+VEHICLE, CONTROL+CANA, CONTROL+VEHICLE. 
Pertinent, statistically significant between-group differences (and p-values) are delineated. 
Abbreviations: (A) PTH, parathyroid hormone; (B) P1NP, procollagen type 1 N-terminal 
propeptide; (C) RatLAPS, C-terminal telopeptides of type I collagen; (D) FGF23, fibroblast 
growth factor-23.
Thrailkill et al. Page 14
Bone. Author manuscript; available in PMC 2017 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. CYP27B1 and SLC34A1 gene expression
Differences (mean ± SD) in renal gene expression (fold-change vs. CONT+VEHICLE) for 
(A) CYP27B1 and (B) SLC34A1 genes are shown. The product of the CYP27B1 gene, 25-
hydroxyvitamin D-1α-hydroxylase, functions to synthesize 1, 25-(OH)2 vitamin D3 from 
25-(OH) vitamin D3; CYP27B1 gene expression is upregulated in response to PTH and to 
hypocalcemia. The SLC34A1 gene encodes for the renal sodium-phosphate co-transporter, 
responsible for phosphate reabsorption in the proximal tubule. Co-transporter function is 
reduced by PTH, contributing to phosphaturia. Statistically significant between-group 
differences (and p-values) are delineated, showing a significant increase in CYP27B1 and 
decrease in SLC34A1 in diabetic mice (STZ+VEHICLE), which is in keeping with the 
increase in mean serum PTH observed in diabetic mice (Figure 2A).
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Table 1
Phenotypic parameters (top); and selected properties of bone (femur metaphysis, femur diaphysis, L6 
vertebra), as determined by uCT, three-point bending and compression testing.
Canagliflozin effects Diabetes effects
Parameter
STZ+CA NA1 STZ+VE H2 CONT+CANA3 CONT+VEH4 PI (+T1D) P2 (no T1D) P3 (+CANA) P4 (no CANA)
(n=19) (n=18) (n=20) (n=20) 1 vs 2 3 vs 4 1 vs 3 2 vs 4
Starting body
weight gm
22.63
(1.70)
24.24
(1.76)
25.53
(2.04)
26.42
(2.33)
0.030
8 NS <.0001 0.0035
Ending body
weight gm
20.54
(3.54)
20.41
(2.21)
26.79
(2.33)
26.70
(2.59) NS NS <.0001 <.0001
Week 3 blood
glucose mg/dL
358.84
(72.30)
520.94
(84.69)
150.25
(18.65)
153.35
(14.50)
<.000
1 NS <.0001 <.0001
Week 10 blood
glucose (sac) mg/dL
338.89
(131.45)
525.18
(53.64)
111.75
(18.50)
101.25
(18.77)
<.000
1 NS <.0001 <.0001
CCR‡ μg/mg
445.16
(194)
589.87
(402.42)
164.20
(88.94)
92.03
(37.65) NS 0.003 <.0001 <.0001
Diaphysis/Cortic
al Bone
Ma. V mm3 0.67(0.04)
0.71
(0.06)
0.59
(0.06)
0.59
(0.06)
0.079
8 NS 0.0002 <.0001
Imin mm4 0.05(0.01)
0.05
(0.01)
0.06
(0.01)
0.06
(0.01) NS NS <.0001 <.0001
Ct.AR (BArea) mm2 0.57(0.05)
0.58
(0.07)
0.72
(0.05)
0.75
(0.05) NS NS <.0001 <.0001
Tt.AR (TArea) mm2 1.09(0.06)
1.13
(0.07)
1.18
(0.09)
1.22
(0.09) NS NS 0.0024 0.004
Ct.TMD mgHA/cm3
1364.11
(11.29)
1368.88
(17.53)
1366.03
(22.23)
1376.81
(12.90) NS NS NS NS
Ct.Th mm 0.16(0.01)
0.16
(0.01)
0.19
(0.01)
0.20
(0.01) NS
0.072
1 <.0001 <.0001
Ct.Po % 2.66(0.31)
2.64
(0.37)
2.14
(0.45)
2.02
(0.23) NS NS <.0001 <.0001
Length mm 13.68(0.35)
13.81
(0.29)
14.11
(0.27)
14.13
(0.26) NS NS <.0001 0.0029
Bending strength MPa 235.77(21.04)
231.86
(40.36)
268.02
(21.92)
274.30
(24.39) NS NS 0.0016 <.0001
Modulus GPa 12.70(1.42)
12.62
(2.19)
14.40
(1.89)
14.16
(1.71) NS NS 0.0188 0.0337
Toughness N/mm 1.55(0.31)
1.41
(0.42)
2.45
(0.75)
2.39
(0.68) NS NS <.0001 <.0001
Peak Moment N.mm 23.56(3.15)
24.32
(5.73)
32.64
(4.48)
35.52
(3.98) NS
0.085
2 <.0001 <.0001
Rigidity N/mm2
597.28
(109.83)
645.51
(175.22)
865.61
(141.01)
909.03
(155.10) NS NS <.0001 <.0001
Slendernessa
mm/m
m2
12.60
(0.61)
12.24
(0.75)
12.02
(0.82)
11.66
(0.77) NS NS 0.0703 0.0703
Normalized PYD mm 0.01(0.01)
0.01
(0.01)
0.04
(0.02)
0.03
(0.02) NS NS <.0001 0.0002
Metaphysis/Trab
ecular Bone
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Canagliflozin effects Diabetes effects
Parameter
STZ+CA NA1 STZ+VE H2 CONT+CANA3 CONT+VEH4 PI (+T1D) P2 (no T1D) P3 (+CANA) P4 (no CANA)
(n=19) (n=18) (n=20) (n=20) 1 vs 2 3 vs 4 1 vs 3 2 vs 4
VOX-BV/TV mm3 0.05(0.01)
0.04
(0.01)
0.07
(0.01)
0.08
(0.01) NS
0.015
7 <.0001 <.0001
Conn.D‡ mm−3
156.05
(53.98)
155.16
(54.51)
119.78
(25.60)
141.07
(29.91) NS NS 0.0256 NS
SMIb --
2.03
(0.19)
2.15
(0.21)
2.39
(0.16)
2.35
(0.14) NS NS <.0001 0.0023
Tb.N mm−1 3.30(0.26)
3.30
(0.27)
3.68
(0.32)
3.97
(0.29) NS
0.004
7 0.0003 <.0001
Tb.Th mm 0.03(0.00)
0.03
(0.00)
0.04
(0.00)
0.04
(0.00) NS NS <.0001 <.0001
Tb.Sp mm 0.31(0.02)
0.31
(0.02)
0.28
(0.03)
0.26
(0.02) NS
0.018
4 0.0003 <.0001
Tb.TMD mgHA/cm3
951.89
(21.87)
962.66
(31.67)
1012.59
(25.13)
1046.00
(21.17) NS
0.000
1 <.0001 <.0001
L6 Vertebra #
Tb.BV/TV mm3 0.15(0.03)
0.15
(0.03)
0.20
(0.03)
0.21
(0.02) NS NS 0.001
<0.000
1
Tb.TMD mgHA/cm3
704.90
(11.81)
715.80
(44.77)
816.70
(16.10)
807.70
(14.76) NS NS
<0.000
1
<0.000
1
Force N 10.53(2.82)
11.63
(5.75)
20.84
(6.23)
22.20
(3.73) NS NS
<0.000
1
<0.000
1
Stress MPa 27.99(8.03)
27.87
(9.13)
37.89
(10.84)
38.62
(6.26) NS NS 0.094 0.055
A comparison of all parameters (mean ± SD) between the four groups is shown. Pairwise p-values are indicated, as follows: PI, STZ+CANA vs. 
STZ+VEH; P2, CONT+CANA vs. CONT+VEH; P3, STZ+CANA vs CONT+CANA; P4, STZ+VEH vs. CONT+VEH.
Abbreviations: CCR, urine Calcium to Creatinine ratio; Alphabetically listed: BV/TV, bone volume/tissue volume; Conn.D, connectivity density; 
Ct.Ar, cortical area; Ct.Po, cortical porosity; Ct.Th, cortical thickness; Ct.TMD, cortical tissue mineral density; Force, peak force in compression; 
Imin, minimal moment of inertia; Ma.V, marrow volume; PYD, post yield deflection; SMI, structural model index; Stress, peak force per area; 
Tb.N, trabecular number; Tb.Sp, trabecular separation; Tb.Th, trabecular thickness; Tb.TMD, trabecular tissue mineral density; Tt.Ar, total cross-
sectional area. Significant differences (p<0.05) are highlighted in bold font; p<0.10 are also shown. NS = no significant difference.
aSlenderness is the ratio of the length to the total cross-sectional area of the femur mid-shaft.
bStructural model index characterizes the shape of trabecular bone (1: plate-like; 3: rod-like).
‡Variables were log-transformed due to violation of the normality assumption.
#Vertebral analyses conducted on n=10 mice per group.
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